The treatment paradigm of NSCLC underwent a major revolution during the course of 2017. Immune checkpoint inhibitors (ICIs) brought remarkable improvements in response and overall survival both in unselected pretreated patients and in untreated patients with programmed death ligand 1 expression of 50% or more. Furthermore, compelling preliminary results were reported for new combinations of anti-programmed cell death 1/ programmed death ligand 1 agents with chemotherapy or anti-cytotoxic T-lymphocyte associated protein 4 inhibitors. The success of the ICIs appeared to extend to patients with SCLC, mesothelioma, or thymic tumors. Furthermore, in SCLC, encouraging activity was reported for an experimental target therapy (rovalpituzumab teserine) and a new chemotherapeutic agent (lurbinectedin). For oncogeneaddicted NSCLC, next-generation tyrosine kinase inhibitors (TKIs) (such as osimertinib or alectinib) have demonstrated increased response rates and progression-free survival compared with first-generation TKIs in patients with both EGFR-mutated and ALK receptor tyrosine kinase gene (ALK)-rearranged NSCLC. However, because of the lack of mature overall survival data and considering the high efficacy of these drugs in patients with NSCLC previously exposed to first-or second-generation TKIs, definitive conclusions concerning the best treatment sequence cannot yet be drawn. In addition, new oncogenes such as mutant BRAF, tyrosine-protein kinase met gene (MET) and erb-b2 receptor tyrosine kinase 2 gene (HER2), and ret protooncogene (RET) rearrangements have joined the list of potential targetable drivers. In conclusion, the field of thoracic oncology is on the verge of a breakthrough that will open up many promising new therapeutic options for physicians and patients. The characterization of biomarkers predictive of sensitivity or resistance to immunotherapy and the identification of the optimal therapeutic combinations (for ICIs) and treatment sequence (for oncogene-addicted NSCLC) represent the toughest upcoming challenges in the domain of thoracic oncology.
Introduction
The year 2017 was one of the most active regarding the field of thoracic malignancy therapeutics. Immune checkpoint inhibitors (ICIs), in particular, anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) and antiprogrammed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) agents ( Fig. 1A and B) , represent the most important recent developments in the management of thoracic tumors. Their role in patients with previously treated advanced NSCLC was consolidated, and they also emerged as key players in patients with untreated advanced NSCLC as monotherapy or in combination. Additionally, at least five early studies showed promising results for ICIs in patients with previously treated advanced SCLC, 1 thymic epithelial tumors, 2, 3 and mesothelioma. 4, 5 In the field of precision medicine, besides EGFR, ALK receptor tyrosine kinase gene (ALK), and BRAF molecular alterations (Fig. 2) , recently emerged new potentially actionable targets included ret proto-oncogene (RET) rearrangements and mutations in erbb2 receptor tyrosine kinase 2 gene (HER2) and EGFR exon 20. Next-generation tyrosine kinase inhibitors (TKIs) proved to be more active than first-generation drugs in patients with EGFR-mutated 6 and ALKrearranged 7, 8 NSCLC, although definitive conclusions cannot be drawn about the best treatment sequence able not only to improve progression-free survival (PFS) but also to positively affect overall survival (OS). In this review we cover the main advances regarding immunotherapy, targeted therapy, and chemotherapy in patients with NSCLC, for both pretreated and treatmentnaive populations, with a particular focus on targeted therapies. 
Methods for Selection of the Studies
We reviewed MEDLINE/PubMed for citations from January 2017 up to December 2017; our search terms included lung cancer, pleural mesothelioma, thymic malignancies, immune checkpoint inhibitors, PD-1/PD-L1 inhibitors, CTLA4 inhibitors, targeted therapy, and chemotherapy. We also used the same terms to search abstracts and virtual meeting presentations from the 2017 European Society of Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO) conferences, the World Conference on Lung Cancer, and the ESMO Immuno Oncology Congress to identify relevant studies. The search included both clinical trials and cohort studies involving patients with thoracic malignancies, regardless of histologic type, treatment, and therapy line.
Advances in Advanced NSCLC: Immunotherapy

Pretreated Patients
The year 2017 saw the efficacy of PD-1/PD-L1 inhibitors unequivocally established in patients with pretreated advanced NSCLC. Considering that a subset of patients with NSCLC treated with ICIs experience very prolonged OS, follow-up data from ICI studies are now of paramount importance. An update of the phase I CA209-003 trial testing nivolumab in 129 patients with previously treated (1-5 prior lines) NSCLC showed that with 58 months of follow-up, the 5-year OS rate was 16% for patients with squamous cell carcinoma and 15% for patients with nonsquamous cell carcinoma, and the median OS was 9.9 months. No clinical or pathological characteristics correlated with response in the 16 patients who survived more than 5 years. 9 Given the long survival in this population, the duration of treatment has become a major topic of debate. In a recent phase III/IV trial (CheckMate 153), continuous nivolumab therapy was compared with observation after 1 year of nivolumab therapy in 220 patients with NSCLC. PFS was better in patients receiving continuous treatment than in those who stopped taking it after 1 year (not reached . 10 The authors proposed that ICIs be used until progression, but additional data are needed to draw definitive conclusions concerning the optimal duration of treatment with PD-1/PD-L1 inhibitors.
Several other ICIs were shown to improve outcome in pretreated NSCLC. The phase III OAK trial assessed the efficacy of atezolizumab versus that of docetaxel in patients with NSCLC in second or later lines. 11 The primary efficacy analysis was performed in 850 patients. The , and the 2-year OS rates were 31% and 21% respectively. The OS benefit was observed regardless of histologic type and PD-L1 expression, although concerns were raised about the appropriateness of the antibody (SP142) used to stain TCs and ICs. PD-L1 expression was thus evaluated with the 22C3 immunohistochemistry assay (Agilent Technologies/Dako), the companion diagnostic of pembrolizumab, in 400 tumors from this study.
ONCOGENE ADDICTED HIGHLY SENSITIVE TO IMMUNO OTHERS
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Atezolizumab was superior to docetaxel in all subgroups, including when tumors had less than 1% PD-L1 expression on TCs. However, these data are still a matter of debate because PD-L1 expression less than 1% was found in 55% of the tumors, whereas the expected rate of negative tumors is around 30%, making it likely that the population with PD-L1 expression less than 1% included patients with false-negative tumors. Other predictive biomarkers were explored in patients treated with atezolizumab. Plasma samples from the phase II POPLAR and phase III OAK studies were retrospectively tested for tumor mutational burden (TMB) by using a 394 gene-based next-generation sequencing assay. 13 A total of 13 cutoff points for TMB positivity were analyzed, and OS was significantly longer with atezolizumab than with docetaxel in all TMB subgroups, with a trend for a lower HR when the number of mutations increased.
Interesting data for avelumab, a human immunoglobulin G1 monoclonal antibody targeting PD-L1 with a shorter half-life than other ICIs (6 days versus 27 days for atezolizumab) were recently presented. Exposureresponse and PD-L1 expression in 184 patients with pretreated NSCLC in the JAVELIN phase 1a trial were reported at the 2017 ASCO meeting.
14 In this PD-L1-unselected population, higher exposure to avelumab was associated with improved overall response rates (ORRs) according to the quartiles (Q1-Q4) of trough concentration after the first dose (8.7% for Q1 versus 17.4% for Q4). When 92 patients from the quartiles Q3 and Q4 (>50% of exposure) were analyzed in terms of PD-L1 expression, the ORRs were 25% (!1%), 26% (!5%), 33% (!50%), and 43% (!80%), respectively. Higher avelumab exposure was associated with a modest increase in immune-related adverse events (irAEs). Of note, the correlation between irAEs and benefit was further explored in a retrospective study that included 134 patients with NSCLC treated with nivolumab in second or later lines. irAEs were reported in 69 patients (51%), 9% of which were grade 3 or 4, and 24 patients (18%) required systemic steroids. The development of irAEs during nivolumab treatment was associated with significant improvements in PFS (HR ¼ 0.525, 95% CI: 0.287-0.937, p ¼ 0.03) and OS (HR ¼ 0.282, 95% CI: 0.101-0.667, p ¼ 0.003). 15 The efficacy of PD-1/-PD-L1 inhibitors in patients with EGFR-mutated or ALK-rearranged NSCLC remains an unresolved issue. Subgroup analyses of clinical trials testing ICIs in patients with pretreated NSCLC 11, 16, 17 and recent data from expanded access programs 18 showed an absence of survival benefit and low ORR (w8%), respectively, in oncogene-addicted tumors. Of 111 patients included in the ATLANTIC phase II trial testing durvalumab in third or later lines, 97 had EGFR-mutated NSCLC, and the ORR was 14.7% in patients with PD-L1 expression of 25% or higher. However, in patients with PD-L1 less than 25%, the ORR was only 5%; furthermore, no objective responses were observed in the 10 evaluable patients with ALK-rearranged NSCLC. 19 Similarly, in the updated results of the phase II BIRCH study testing atezolizumab in the first-line setting, a promising ORR (31%) and median PFS (7.6 months) were reported for 13 patients with EGFR-mutated PD-L1-positive (TC2/3 or IC2/3) NSCLC, 20 suggesting a potential benefit of ICIs in oncogene-addicted NSCLC if appropriately selected for PD-L1 expression. Finally, intriguing data showed a significant upregulation of PD-L1 expression in patients with T790M-negative EGFR-mutated NSCLC compared with in those with T790M-positive EGFRmutated NSCLC. 21 On this basis, CheckMate 772 is currently exploring the use of nivolumab in combination with ipilimumab or chemotherapy in pretreated EGFRmutated T790M-negative NSCLC. 22 Finally, during the course of the year, several studies in different tumor types described accelerated tumor growth during ICI treatment. 23, 24 This phenomenon, known as hyperprogressive disease (HPD), was recently defined as Response Criteria in Solid Tumors progression at first evaluation during ICI treatment associated with a more than 50% increase in the tumor growth during ICIs compared with growth before initiation of immunotherapy. According to this definition, HPD was retrospectively identified in 14% of patients with advanced NSCLC treated with ICIs and in a lower proportion (5%) of patients treated with single-agent chemotherapy. 25 In 26 A total of 82 of 151 patients (62.3%) in the chemotherapy arm crossed over to pembrolizumab in second-line treatment; the ORR was 20.7%, which is surprisingly low for a high-PD-L1-expressing population, suggesting the importance of early introduction of immunotherapy in PD-L1-positive patients. A twin phase III study (Checkmate 026), comparing nivolumab at 3 mg/kg every 2 weeks with platinum-based chemotherapy every 3 weeks for six cycles in patients with advanced or recurrent NSCLC with 1% or higher PD-L1 tumor expression was recently published. 27 The primary end point was PFS, as assessed by blinded independent central review in patients with NSCLC with at least 5% PD-L1 expression. Among 423 patients, nivolumab failed to significantly improve PFS (HR ¼ 1.15, 95% CI: 0.91-1.45, p ¼ 0.25). When the threshold of PD-L1 positivity was increased to 50%, the lack of benefit for nivolumab persisted, with an HR for progression or death of 1.07 (95% CI: 0.77-1.49). Median OS was 14.4 months (95% CI: 11.7-17.4) with nivolumab and 13.2 months (95% CI: 10.7-17.1) with chemotherapy (HR ¼ 1.02, 95% CI: 0. 80-1.30 ). An exploratory analysis in 312 patients (58% of randomized patients) assessed the impact of TMB on outcomes. A high TMB was reported in 30% of patients receiving nivolumab versus 39% in the chemotherapy group. The ORR (47% versus 28%) and median PFS (9.7 versus 5.8 [HR ¼ 0.62, 95% CI: 0.38-1) were improved by nivolumab compared with by platinum-based chemotherapy in the high-TMB population. Surprisingly, no difference was seen in OS, potentially because of a 68% crossover rate to second-line immunotherapy in the chemotherapy cohort.
Efficacy data for atezolizumab in the first-line setting were also recently updated. The phase II BIRCH trial assessed atezolizumab in patients with untreated PD-L1-positive NSCLC. 20 To be eligible, tumors had to express PD-L1 (with SP142) on at least 5% of TCs or ICs (TC2/3 or IC2/3). Among 139 patients, the ORR was 35% for the TC3 or IC3 subgroup (TCs !50% or ICs !10%). The median OS times were 24.0 months (95% CI: 18.1-30.8) for the overall population and 26.9 months (95% CI: 12.0-NE) for TC3 or IC3 patients. These results were consistent with the efficacy data of pembrolizumab in patients with untreated PD-L1-positive NSCLC.
In the open-label, multicenter, phase III MYSTIC trial (NCT02453282), 1092 patients with treatment-naive EGFR/ALK wild-type NSCLC with PD-L1 expression of 25% or higher were randomized to receive durvalumab plus tremelimumab, durvalumab, or platinum-based chemotherapy. The coprimary end points were OS and PFS. 28 Results have yet to be published; however, the trial failed to show superiority in PFS of the combination durvalumab plus tremelimumab compared with platinum-based chemotherapy. As the efficacies of nivolumab, pembrolizumab, and durvalumab are similar in patients with pretreated NSCLC, it is more likely that the differences observed in patients with untreated PD-L1-positive NSCLC reflect heterogeneous patient selection.
In May 2017, the FDA approved pembrolizumab in combination with pemetrexed and carboplatin as firstline treatment of advanced nonsquamous NSCLC regardless of PD-L1 expression; the approval was based on the results of the phase I/II KEYNOTE 021 study, in which 123 patients with advanced nonsquamous NSCLC were randomized 1:1 to receive pembrolizumab combined with carboplatin-pemetrexed versus carboplatinpemetrexed. 29 Updated OS data were recently reported (18.7 months median follow-up versus prior follow-up of 10.2 months). 30 Both ORR (56.7% versus 31.7%) and median PFS (19.0 versus 8.9 months) (HR ¼ 0.54, p ¼ 0.0067) were significantly higher with the addition of pembrolizumab. A positive nonsignificant improvement in OS was also reported (NR versus 20.9 months). It is unknown whether the OS benefit of the experimental arm is driven by the patients with high-PD-L1 NSCLC because the subgroup analyses were not updated. The impressive PFS in the control arm may reflect a selected population. It is hoped that the confirmatory phase III trial (KEYNOTE 189 31 ) will establish approval for this indication.
At the 2017 ESMO Immuno Oncology Congress, the results of IMpower150 (NCT02366143), a multicentric open-label phase III trial evaluating the combination of atezolizumab with platinum-based chemotherapy plus bevacizumab, were presented. 32 In this study, 1202 treatment-naive patients with advanced nonsquamous NSCLC were randomized (1:1:1) to atezolizumab in combination with carboplatin plus paclitaxel (arm A) or in combination with carboplatin plus paclitaxel and bevacizumab (arm B) compared with carboplatin plus paclitaxel and bevacizumab (arm C). After the induction phase, the patients received maintenance treatment with atezolizumab (arm A), atezolizumab plus bevacizumab (arm B), or bevacizumab alone (arm C), until disease progression. The arm B demonstrated improved PFS (coprimary end point) compared with the arm C, both in an intention-to-treat population (8.3 months versus 6.8 months [HR ¼ 0.62, 95% CI: 0.52-0.74, p < 0.0001]) and in a subgroup of patients defined by T-effector gene signature expression (11.3 months versus 6.8 months [HR ¼ 0.51, 95% CI: 0.38-0.68, p < 0.0001]). Benefit was seen irrespective of the PD-L1 expression but with less relevant clone SP142, and more data are needed to define the best scenario for patients with PD-L1-positive (>50% TCs stained and clone other than SP142) NSCLC. The combination of atezolizumab plus carboplatin, paclitaxel, and bevacizumab also showed a promising OS; however, more mature results are expected in the first half of 2018.
Currently, there are few studies evaluating immunotherapy combinations in NSCLC. The CheckMate 012 phase I, multicohort study evaluated safety and efficacy of nivolumab plus ipilimumab in treatment-naive patients with advanced NSCLC. Patients were randomized (1:1:1) to receive 1 mg/kg of nivolumab every 2 weeks plus 1 mg/kg of ipilimumab every 6 weeks, 3 mg/kg of nivolumab every 2 weeks plus 1 mg/kg of ipilimumab every 12 weeks, or 3 mg/kg of nivolumab every 2 weeks plus 1 mg/kg of ipilimumab every 6 weeks. Of the 77 patients treated, 38 received nivolumab every 2 weeks plus ipilimumab every 12 weeks and 39 patients received nivolumab every 2 weeks plus ipilimumab every 6 weeks. The combination demonstrated a high rate of grade 3 or 4 adverse events (AEs) compared with nivolumab alone, with AE rates of 37% and 33% in the ipilimumab every 12 weeks cohort and ipilimumab every 6 weeks cohort, respectively. However, the combination showed impressive responses, with ORRs of 47% in the ipilimumab every 12 weeks cohort and 38% in the ipilimumab every 6 weeks cohort. Higher response rates were observed in patients with PD-L1 expression of at least 1% (ORR in 57% in both cohorts). 33 In the CheckMate 012 study, the combination of nivolumab with platinum-based chemotherapy gave an ORR of 46% and 25% 3-year OS in 56 patients with untreated NSCLC. Interestingly, long-term survivors included patients who were never-smokers or who had PD-L1 expression less than 1%. 34 
Advances in Advanced NSCLC: Targeted Therapies
Given the existence of matched targeted therapies and individual strategies, patients with advanced oncogene-addicted NSCLC must be considered separately. The targetable oncogenic drivers identified so far are EGFR mutations (11% in whites 35 and 47% in Asians 36 ), ALK rearrangements (5%), BRAF mutations (2%), and ROS1 rearrangements (1%). 35 Additional actionable genetic aberrations explored over the past year included tyrosine-protein kinase met gene (MET) mutations, HER2 mutation or amplification, and RET and neurotropic tropomyosin receptor kinase gene (NTRK) rearrangements.
EGFR Mutations
Treatment of EGFR-mutant adenocarcinoma was widely reshaped during 2017 by the introduction of compelling new drugs in patients with both TKI-naive and pretreated NSCLC. Table 1 6,37-44 summarizes efficacy results of the major clinical trials in patients with EGFR-mutated NSCLC published or presented during 2017. Figure 4 represents possible sequential treatment strategies and corresponding cumulative PFS with first-and next-generation EGFR TKIs in EGFR-mutated NSCLC.
First-Generation Inhibitors: Gefitinib, Erlotinib, Icotinib. In the first-line setting, the phase III CONVINCE trial comparing icotinib, a first-generation TKI, with cisplatin-pemetrexed (with optional maintenance pemetrexed) in Chinese patients with EGFR-mutated NSCLC, showed a significant benefit in PFS (11.2 versus 7.9 months [p ¼ 0.006]). No difference in OS was observed on account of poststudy therapy with an EGFR TKI, which was reported in 82% of chemotherapytreated patients. 37 When indirectly compared with other first-generation inhibitors such as gefitinib and erlotinib, icotinib did not outperform. 45 Upon resistance to first-generation inhibitors, the updated results of the IMPRESS phase III trial confirmed the deleterious effect on OS of continuing gefitinib in addition to cisplatinpemetrexed versus standard treatment of cisplatinpemetrexed. 42 Second-Generation Inhibitors: Afatinib, Dacomitinib. The benefit of second-generation over first-generation inhibitors has been strongly debated since publication of the LUX-LUNG 7 trial showing the absence of a clinically meaningful survival benefit with afatinib versus with gefitinib in patients with untreated EGFR-mutated NSCLC. 39 Significant data came from the ARCHER 1050 study, the first open-label phase III trial comparing dacomitinib with gefitinib in patients with NSCLC without brain metastases who harbored a common activating EGFR mutation (del19/L858R). After 14.7 months of follow-up, dacomitinib was found to have the longest PFS among first-or second-generation EGFR TKIs. Interestingly, the PFS curves in the ARCHER 1050 study separated relatively late, after at least 6 months, as in the LUX-LUNG-7 trial. ORR was similar between gefitinib and dacomitinib, suggesting that the PFS benefit was driven mainly by a greater depth of response with dacomitinib because of more potent EGFR inhibition. However, the attractiveness of dacomitinib was hampered by a high rate of treatment-related serious AEs (9.3%) leading to frequent dose reductions (66%) and treatment discontinuation (w10%). 38 The OS data are currently immature but will likely be influenced by subsequent therapies. Dacotiminib could be a potential first-line option after carefully weighing the toxicity-tobenefit ratio.
Third-Generation Inhibitor: Osimertinib. Osimertinib is a third-generation irreversible EGFR TKI that is selective for both EGFR and T790M mutations. In the AURA3 phase III trial, compared with platinumpemetrexed chemotherapy, osimertinib significantly improved ORR (71% versus 31% [p < 0.001]) and PFS (10.1 versus 4.4 months [p < 0.001]) in patients with T790M-positive EGFR-mutated NSCLC previously treated with first-or second-generation EGFR TKIs. 40 In AURA3, baseline central nervous system (CNS) imaging was mandated only in patients with known or suspected brain metastases and follow-up imaging in patients with confirmed CNS disease. Of note, osimertinib was extremely active against brain metastases and leptomeningeal disease, with a significantly higher CNS ORR (70% versus 31%) and PFS (11.7 versus 5.6 months) compared with chemotherapy. 46 The activity was observed regardless of prior radiotherapy (RT) status (64% in patients with prior RT versus 34% in patients who did not receive prior brain RT). At the 2017 annual ASCO meeting, a phase III trial comparing third-line osimertinib with docetaxel plus bevacizumab in patients with T790M-positive EGFR-mutated NSCLC reported a remarkable improvement in PFS (10.2 versus 3 months [p < 0.0001]) and in ORR (62% versus 8%) in favor of osimertinib. 4 Osimertinib had a manageable toxicity profile, the most common side effects being diarrhea and rash, with grade 3 or 4 in only 1% to 3% of patients. 40, 41 On the basis of the AURA3 study, osimertinib received FDA and EMA approval in patients with pretreated T790M-positive EGFR-mutated NSCLC.
The FLAURA study, a phase III trial comparing firstline osimertinib with gefitinib in patients with NSCLC harboring the common EGFR mutation del19/L858R was reported this year. Osimertinib significantly improved PFS (18.9 versus 10.0 months [p < 0.001]) compared with first-generation EGFR TKIs (gefitinib or erlotinib). 6 The ORR was 80% for osimertinib and 76% for standard EGFR TKI. As in AURA3, in the FLAURA study, CNS baseline and follow-up imaging was mandatory only for patients with known brain metastases. In this subset of patients, osimertinib showed a 76% ORR, which is in line with that for the overall population. A nonsignificant OS benefit was observed in favor of osimertinib; the rate of crossover to osimertinib in the control arm was limited and the data are still immature. Approval of osimertinib in the first-line setting is expected on the basis of the PFS results, but the optimal strategy is still unknown. In particular, the control arm (gefitinib) might be considered suboptimal given the results of dacomitinib or other combinations such as erlotinib/bevacizumab (the BELIEF trial), with PFS ranging from 14.7 to 16.0 months. 38, 43 It is hoped that the APPLE phase II trial comparing osimertinib up front with gefitinib followed by osimertinib will give further insight into this issue. 47 Remarkable advances have been observed in the detection and monitoring of EGFR mutations in circulating tumor DNA (ctDNA). A large-scale study including patients with NSCLC with insufficient tumor tissue for EGFR analysis, showed that patients with EGFR positivity in ctDNA had outcomes similar to those with tissue diagnosis, with an ORR of 72% and PFS of 11 months with first-line EGFR TKIs. 48 In patients who failed therapy with a first-and/or second-generation EGFR TKI, the 50% rate of T790M mutation positivity in ctDNA was similar to that expected in tissue, as was the 62% ORR with osimertinib, 49 confirming the initial results from the phase I AURA study. 50 Interestingly, an exploratory analysis of the AURA trial reported that clearance of EGFR mutations (del19/L858R or T790M) at 6 weeks after initiation of osimertinib was associated with improved ORR and PFS compared with absence of plasma clearance, highlighting the potential role of ctDNA monitoring to assess EGFR TKI efficacy. 51 In the AURA study, next-generation sequencing on ctDNA was used to characterize mechanisms of resistance to osimertinib in 33 patients: C797S mutation was identified in seven patients, MET amplification in three patients, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) in three patients, and KRAS and BRAF V600E mutations and FGFR3 and RET rearrangement in one patient each. Interestingly, loss of T790M was associated with early onset of resistance to osimertinib, and furthermore, the C797S mutation was found exclusively in patients maintaining the T790M mutation, whereas other competing mechanisms of resistance were more frequent in patients losing T790M. 52 Finally, SCLC transformation has been described as a mechanism of resistance to EGFR TKIs in 5% of patients with EGFR-mutant NSCLC. 53 A recent study elegantly demonstrated that the clone responsible for SCLC transformation is present at baseline in patients with EGFR-mutated NSCLC, and biallelic loss of retinoblastoma 1 gene (RB1) and tumor protein p53 gene (TP53) correlates with a 43-fold increased risk of transformation to SCLC. 54 This study suggested that testing for tumor protein 53 and retinoblastoma 1 at diagnosis in EGFR-mutated NSCLC could be useful to predict tumors that are most likely to transform to SCLC, prompting clinicians to monitor this disease more frequently than in other patients.
Exon 20 EGFR Mutations. Exon 20 insertions represent 9% of all EGFR mutations and are not appropriate targets for current EGFR TKIs because of lack of activity. 55 The EGFR inhibitor poziotinib showed promising results in in vitro models of exon 20 EGFR-mutated NSCLC, whereas eight of 11 patients (73%) with exon 20 EGFR mutations experienced a response to poziotinib in a phase II study. Despite the promising activity, PFS results and further patient data are needed. 44 
ALK Rearrangement
ALK-rearranged NSCLC is the oncogene-addicted setting showing the greatest evolution over the past year. This population experiences a remarkably long OS, up to 7.5 years, when appropriately treated. 56 Not all ALK fusions are alike, given that 3a/b variants were less sensitive to anaplastic lymphoma kinase (ALK) TKIs, Figure 4 . Sequential treatment strategies and cumulative progression-free survival (PFS) with first-and next-generation (gen) EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutated NSCLC. ph, phase; Bvz, bevacizumab.
probably because of higher protein stability. [57] [58] [59] Secondary ALK resistance mutations can be actively monitored in cell-free DNA to better characterize mechanisms of resistance. 60 Table 2 7,8,61-68 summarizes the major clinical trials in patients with ALK-rearranged NSCLC during 2017. Despite extremely encouraging results, a lot of questions regarding the best treatment strategies and combinations remain unanswered, as depicted in Figure 5 .
First-Generation Inhibitor: Crizotinib. At the 2017 ESMO meeting, the updated OS analysis of PROFILE 1014, a phase III trial comparing first-line crizotinib with platinum-pemetrexed chemotherapy in patients with ALK-rearranged NSCLC, reported an impressive 56% 4-year OS with crizotinib. OS was not statistically different because of the high crossover rate (w85%). Patients receiving crizotinib followed by other ALK TKIs had a very long median OS compared with those receiving first-line crizotinib followed by chemotherapy (NR versus 49 months). 61 Second-Generation Inhibitors: Ceritinib, Alectinib, Brigatinib. Compared with second-or third-line chemotherapy (docetaxel or pemetrexed), ceritinib significantly improved ORR (39% versus 7%) and PFS (5.4 versus 1.6 months [p < 0.0001]) in patients with crizotinib-resistant ALK-rearranged NSCLC in the phase III trial ASCEND-5. No significant difference was seen in OS, likely because of the 75% rate of crossover from chemotherapy. 62 Ceritinib also showed dramatically improved ORR (72% versus 27%) and PFS (16.6 versus 8.1 months [HR ¼ 0.55, p < 0.00001]) compared with first-line platinum-pemetrexed chemotherapy with maintenance pemetrexed in the phase III trial ASCEND-4. 63 As observed in PROFILE 1014 and ASCEND-5, a significant difference in OS was not expected owing to the 72% crossover rate. In 2017, ceritinib obtained FDA and EMA approval in patients with untreated ALKpositive NSCLC. Activity in brain metastases was reported, with an intracranial ORR of 73% in first-line treatment and 35% in second-line treatment. 62, 63 Interestingly, around 60% of patients enrolled in ASCEND 4 and 40% of patients in ASCEND 5 had not received any brain RT before. Ceritinib, 750 mg/d, led to grade 3 or 4 AEs in 65% of patients in ASCEND-4 (mostly asymptomatic increases in alanine transaminase [ALT], aspartate transaminase, or g-glutamyl transferase levels), and dose reductions or discontinuation were common (in 80% of patients) in both ASCEND-4 63 and ASCEND-5.
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The phase I study ASCEND-8 recently showed that ceritinib, 450 mg/d with a low-fat meal, had a similar pharmacokinetic profile and the same efficacy (an ORR of 78% and PFS of 17.6 months) as ceritinib, 750 mg/d under fasting conditions. 64 Although increased aspartate transaminase and ALT levels were similar for the two doses, the lower dose was associated with almost no grade 3 gastrointestinal toxicities, half as many grade 2 toxicities, and a similar rate of grade 1 toxicities. Ceritinib, 450 mg with a low-fat meal, is thus a valid alternative regimen for routine practice.
Two phase III studies, ALEX and J-ALEX, recently compared alectinib with crizotinib in white and Japanese patients with ALK-positive NSCLC, respectively. In the J-ALEX, alectinib at 300 mg daily significantly improved ORR (85% versus 70%) and PFS (HR ¼ 0.34) after adjustment for potential imbalance of prognostic factors and time to brain progression (HR ¼ 0.16) compared with crizotinib. 7 Alectinib showed a significant improvement in PFS also in patients with baseline brain metastases (NR versus 10.2 [p ¼ 0.006]); however, the presence of CNS disease was not a stratification factor in J-ALEX, and only 29 and 14 patients had baseline brain metastases in the crizotinib and alectinib arms, respectively. The OS data were still immature; however, crossover from crizotinib to alectinib was allowed. Similarly, the ALEX trial confirmed the superiority of alectinib, 600 mg daily, compared with crizotinib in ORR (83% versus 75%) and in PFS (26 versus 10 months [HR ¼ 0.50, p < 0.001]). The OS data were immature, and surprisingly, crossover was not allowed. 8 Grade 3 to 5 AEs occurred in 26% and 41% of patients in J-ALEX and ALEX, respectively and alectinib had a more favorable AE profile than crizotinib. In both arms, approximately 85% of patients with brain metastases did not receive previous brain RT, and alectinib was clearly superior to crizotinib in CNS responses (intracranial ORR 79% versus 40% [HR ¼ 0.4 for PFS]) and had a remarkable neuroprotective effect, with 5% of patients without CNS involvement having brain progression compared with 31% in the crizotinib arm. 69 Despite the undoubted beneficial effect on the CNS with alectinib, in the ALEX trial a brain evaluation at baseline and every 2 months was mandated for all the patients regardless of the presence of brain metastases, and for this reason, patients were probably overmonitored for brain metastases compared with in other studies performing a CNS evaluation only in patients with known brain metastases at baseline. Finally, on the basis of ORR (36% versus 11%) and PFS (9.6 versus 1.4 months [p < 0.001]) in the phase III ALUR trial, alectinib was more active than third-line chemotherapy in crizotinib-refractory patients. 65 Brigatinib was tested after crizotinib progression with two schedules (90 mg/d or 180 mg/d with a 7-day lead-in at 90 mg/daily) in the randomized phase II trial ALTA. At 180 mg/d, brigatinib showed an ORR of 54%, intracranial ORR of 67%, and PFS of 13 months (investigator assessment). 66 In a crizotinib-resistant setting, these results compared favorably with the PFS times of 5.4 and 9.6 months with ceritinib and alectinib in ASCEND-5 62 and ALUR, 65 respectively. Brigatinib also performed well in a patient with a G1202R ALK mutation, which is a common mechanism of resistance to crizotinib, ceritinib, and alectinib. One of the specific toxicities associated with brigatinib is early-onset pneumonia, which was reported in 6% (all grades) of patients starting treatment with brigatinib at 90 mg/d. Brigatinib is currently being compared with crizotinib in the phase III trial ALTA 1L. 70 Third-Generation Inhibitor: Lorlatinib. Lorlatinib is a potent ALK and ROS1 inhibitor with high CNS penetration and activity against mutations driving resistance to crizotinib, ceritinib, and alectinib, including G1202R. 71 In a nonrandomized multicohort phase I/II trial, the ORR with lorlatinib was 90% in 30 TKI-naive patients (PFS NR), 69% in 59 crizotinib-treated patients (PFS NR), and 39% in 111 patients who had received two or three previous ALK TKIs (PFS 6.9 months). Impressive intracranial responses are reported, including a 48% ORR in the latter heavily pretreated cohort. Grade 3 or 4 treatment-related AEs were reported in 41% of patients (notably hyperlipidemia), and cognitive effects were present but mainly mild and reversible. 67 A phase III trial (CROWN) comparing lorlatinib with crizotinib is ongoing. 72 Ensartinib, a potent ALK, tyrosine-protein kinase met (MET), and ROS1 inhibitor, gave an ORR of 87% and PFS of 26 months in a cohort of patients with TKI-naive ALK-positive NSCLC. 68 The phase III eXalt3 trial is currently testing ensartinib versus crizotinib in the first-line setting.
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ROS1 and NTRK Rearrangements
Crizotinib is the current standard treatment in ROS1-rearranged NSCLC, after a 72% ORR and median PFS of 19.2 months reported in 50 TKI-naive patients. 74 Ceritinib also showed a promising ORR and PFS (62% and 19 months, respectively) in a TKI-naive population. 75 In 32 patients with untreated ROS1-rearranged NSCLC, entrectinib, a ROS and neurotropic tropomyosin receptor kinase (NTRK) TKI, showed an ORR of 78%, an intracranial response of 83%, and an impressive preliminary PFS of 29.6 months. 76 Second-line TKIs are being developed. In 47 ROS1-positive patients, 70% of whom were crizotinib resistant, lorlatinib gave an ORR of 36%, an intracranial ORR of 56%, and a PFS of 9.6 months. 70 G2032R mutations were recently identified in several small series as one of the most frequent mechanisms of resistance to ROS1 inhibition, 77 and in preclinical studies most ROS1 next-generation TKIs (ceritinib 78 , lorlatinib, 79 and entrectinib 80 ) poorly inhibited G2032R-mutant tumors. On the contrary, cabozantinib, which is a multikinase inhibitor with ROS1 activity, demonstrated encouraging concentrations that inhibit 50% in ROS1 G2032R-mutant models. 81 The results of a phase II trial testing cabozantinib in patients with ROS1-rearranged NSCLC are awaited. 82 The NTRK fusion gene was recently reported in up to 3.3% of patients with NSCLC negative for other common molecular drivers, but the results are preliminary and the incidence might be overestimated. 83 In addition to entrectinib, which showed impressive activity with complete intracranial response in a patient with sequestosome 1 gene (SQSTM1)-neurotrophic receptor tyrosine kinase 1 gene (NTRK1)-rearranged NSCLC included in the pooled analysis of the ALKA and STARTRK studies, 84 larotrectinib (LOXO-101), which is a pan-TRK inhibitor, gave an ORR of 78% in adult and pediatric patients with different tumor types in a phase II study; all five patients with lung cancer had a partial response. 85 These results led the FDA to grant orphan drug designation to larotrectinib for the treatment of solid tumors with neurotropic tropomyosin receptor kinase fusion proteins. Table 3 67,75,76,84-95 summarizes the major clinical trials in patients with ROS1-or NRTKrearranged NSCLC during 2017.
BRAF and KRAS Mutations
The BRAF V600E mutation, which has been identified in 1% to 2% of lung adenocarcinomas, 96 recently joined the list of targetable oncogenic drivers. The combination dabrafenib plus trametinib was highly active in patients with pretreated BRAF V600E-mutated NSCLC, with an updated OS of 18 months. 97 Recently, the combination showed an ORR of 64% and PFS of 11 months and a preliminary OS of 25 months in 36 treatment-naive patients. The toxicity profile was similar to that of equivalent agents, with drugrelated grade 3 or 4 AEs in 36% of patients, the most common being pyrexia. 86 On the basis of these results, the combination of dabrafenib and trametinib recently obtained EMA and FDA approval in patients with BRAF V600E-mutated NSCLC regardless of prior treatment.
In contrast, the use of single-agent MEK inhibitors combined with chemotherapy in patients with KRASmutated NSCLC has been unsuccessful. Selumetinib, a highly selective MEK1/2 inhibitor was tested in combination with docetaxel in the phase III SELECT-1 trial. 87 No significant improvements were seen in ORR, PFS, or OS for the combination compared with docetaxel monotherapy in patients with previously treated KRASmutated NSCLC. More recently, abemaciclib, a selective inhibitor of cyclin-dependent kinase 4 and cyclindependent kinase 6, has been compared with erlotinib in a phase III trial (JUPINER) enrolling patients with KRAS-mutated pretreated NSCLC. 98 Results have not been published yet; however, JUPINER did not meet the primary end point of OS. Table 3 summarizes the results of major clinical trials in patients with BRAF-and KRASmutated NSCLC from 2017.
RET Rearrangement
RET rearrangements are found in 1% to 2% of lung adenocarcinomas. 99 Several multitarget agents with anti-RET activity, including vandetanib, cabozantinib, lenvatinib, alectinib, and sunitinib, have been evaluated, with ORRs ranging from 16% to 47% and median PFS from 2.3 to 7.3 months. 88, 89, 100, 101 In 2017, two nonrandomized phase II trials investigated vandetanib in Japanese (LURET) 88 and Korean 89 populations with RETrearranged NSCLC. The ORR, median PFS, and OS were 53% and 5 and 11 months in the LURET study and 18% and 4.5 and 11.6 months in the Korean trial. In both studies the ORR was higher in patients with kinesin family member 5B gene (KIF5B)-RET fusion than in patients with the KIF5B-RET fusion (83% versus 20% in LURET and 33% versus 0% in the Korean trial) and the main treatment-related grade 3 to 4 AEs were hypertension and QT prolongation. A large retrospective worldwide analysis (GLORY) including 165 patients with RET-rearranged NSCLC treated with multitarget agents (vandetanib, cabozantinib, lenvatinib, sunitinib, sorafenib, alectinib, ponantinib, or regorafenib) also reported a disappointing ORR (26%), PFS (2.3 months), and OS (6.8 months). 102 Different mechanisms of escape to RET inhibition and some potential treatment strategies to overcome resistance have recently been described. 103 The early onset of acquired resistance (as described for MDM2 proto-oncogene [MDM2] amplification 104 ) and the existence of concomitant molecular alterations [105] [106] [107] suggest that a combinatorial treatment strategy could be more effective than single-agent RET inhibition. This was also confirmed in a phase I study testing vandetanib and everolimus, which showed a preliminary ORR of 83% in a small series of patients with RET-rearranged NSCLC. 108 In addition, selective RET inhibitors such as LOXO-292 or BLU-667 are being developed with promising activity in both in vitro and in vivo models and in patients with KIF5B-RET fusions. 109 Table 3 summarizes the major clinical trials in patients with RET-rearranged NSCLC from 2017.
MET Deregulation
MET amplification and exon 14 mutations were initially detected in 3.3% of NSCLC, and both were negative prognostic factors for OS. 110 The existence of an overlap between EGFR and MET signaling in preclinical models 111 brought combined approaches blocking EGFR and MET in the absence of EGFR activating mutations. However, two phase III trials (ATTENTION 112 and METlung 90 ) testing erlotinib in combination with a MET inhibitor (tivantinib and onartuzumab, respectively) recently failed to show meaningful benefit. These results were confirmed by a negative randomized phase II trial exploring first-line erlotinib in combination with the MET inhibitor emibetuzumab in patients with EGFRmutated NSCLC, although an exploratory analysis suggested a potential PFS benefit in high expressors of MET. 91 MET amplification was recently found to be a mechanism of resistance to osimertinib in EGFR-mutated NSCLC. 113 The expansion cohort of the phase Ib TATTON trial testing combined osimertinib and savolitinib, which is a MET inhibitor, in patients with EGFR-mutated and MET-positive NSCLC was presented at the 2017 World Conference on Lung Cancer. In patients centrally confirmed as MET positive by fluorescence in situ hybridization (MET gene copy !5 or MET/centrometer chromosome 7 ratio !2), the ORR was 40% in the overall population, 53% to 57% in patients who had not received a third EGFR TKI, and 28% in patients previously treated with a third-generation TKI. 92 The MET exon 14 skipping mutation is an oncogenic driver that can be successfully targeted with MET TKIs, as recently described in a multicentric retrospective study in patients with MET-mutated NSCLC, with OS extended to 25 months in patients treated with a MET TKI compared with 8 months in patients who were not. 114 This result confirmed reports from the expansion cohort of the PROFILE 1001 trial, which showed clinical activity of crizotinib in 10 of 15 patients with NSCLC with the MET exon 14 mutation.
115 Table 3 summarizes the major clinical trials in patients with METderegulated NSCLC from 2017.
HER2 Deregulation
HER2 amplifications and mutations are present in 2% to 6% and 1% to 5% of NSCLC, respectively. 116, 117 Attempts to target it have been mostly unsuccessful. A phase II trial 93 and a retrospective multicentric analysis 118 of afatinib in patients with HER2-mutated NSCLC showed ORRs of 0% and 15%, respectively, confirming the previous low ORR reported with dacomitinib (12%), 119 neratinib (0%), and neratinib plus temsirolimus (19%). 120 Furthermore, in tumors overexpressing erb-b2 receptor tyrosine kinase 2 (HER2) (immunohistochemistry [IHC] score of 2þ or 3þ), the ORR of trastuzumab emtansine (TDM-1) was also disappointing (0% and 20%, respectively). 94 However, in 18 HER2-mutant patients enrolled in a phase II trial the ORR was 44% and the median PFS was 5 months. 95 Interestingly, among responders, HER2 expression with IHC varied widely and was not predictive of benefit with T-DM1, suggesting that HER2 mutation may be a more promising target for TDM-1 therapy than HER2 overexpression. Table 3 summarizes the major clinical trials in patients with HER2-deregulated NSCLC from 2017.
Advances in NSCLC: Chemotherapy
The year 2017 did not bring any major revolutions in chemotherapy for patients with NSCLC. A combined analysis of the MILES-3 and MILES-4 trials evaluated the addition of first-line cisplatin, 60 mg/m 2 every 3 weeks, to gemcitabine or pemetrexed in patients with NSCLC who are older than 70 years. 121 Unfortunately, these two trials were closed prematurely, with a trend to a worse OS in elderly patients with NSCLC when cisplatin was added.
The AvaALL phase III trial showed no difference in OS (primary end point) when first-line bevacizumab was continued beyond progression in patients with NSCLC treated with a chemotherapy platinum doublet. 122 A subgroup analysis of ULTIMATE IFCT 1103 phase III trial, comparing second or third-line paclitaxel plus bevacizumab with docetaxel showed prolonged OS (>12 months) with the combination in patients naive to bevacizumab. 123 Additionally, the activity of second-line antiangiogenic treatment is particularly valuable in patients who are refractory to first-line platinum-based chemotherapy. In an exploratory analysis of the REVEL trial, the OS benefit with ramucirumab plus docetaxel compared with singleagent docetaxel was higher in patients who relapsed within 9 weeks after starting first-line chemotherapy (8.3 versus 4.6 months). 124 Finally, the IFCT-GFPC 1101 trial showed no OS difference between pemetrexed continuation maintenance after cisplatin-pemetrexed treatment compared with a maintenance regimen (switch to pemetrexed or continuous gemcitabine) based on the ORR to cisplatingemcitabine induction chemotherapy. 125 Advances in SCLC and Mesothelioma: Targeted Therapy and Chemotherapy
SCLC
The phase III CONVERT trial compared the standard regimen of RT consisting of 45 Gy twice daily over 3 weeks to 66 Gy once daily over 45 days in combination with cisplatin-etoposide in limited-stage SCLC. 126 No significant survival benefit was observed, and twicedaily concurrent RT remains the standard. The 2-year OS rate was similar in both arms (50%-56%), which is numerically higher than the historical rates with concurrent RT (41%-47%), 127 whereas the rates of radiation esophagitis and pneumonitis were remarkably inferior to those in previous studies of concurrent RT. These findings highlight improvements in staging procedures (i.e., positron emission tomography/computed tomography scan) and the use of modern and precise RT techniques in limited-stage SCLC.
Several ongoing studies are exploring the activity of ICIs in the population of those with SCLC. In the phase Ib KEYNOTE-028 trial, the safety and efficacy of pembrolizumab at 10 mg/kg every 2 weeks for 2 years was assessed in 24 patients with advanced SCLC with at least 1% PD-L1 expression. 1 The safety profile was similar to that in previous studies, and grade 3 or 4 AEs occurred in 8% of patients. The ORR was 33% (95% CI: 16% to 55%) with one complete and seven partial responses, suggesting promising activity in patients with previously treated SCLC. Similarly, the randomized expansion cohort of the phase I/II CHECKMATE 032 trial showed that nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg every 3 weeks) for four cycles nearly doubled ORR (21% versus 11%) compared with nivolumab (3 mg/kg every 2 weeks) in patients with platinum-treated SCLC. However, the rate of grade 3 or 4 toxicities was also higher in the combination arm (37% versus 12%). 128 Rovalpituzumab tesirine (Rova-T) is a delta like Notch canonical ligand 3 (DLL3)-targeted antibody drug conjugate that was developed in patients with recurrent SCLC. 129 Rova-T showed a promising ORR (35%), PFS (4.3 months), and 1-year OS rate (30%) in patients with high DLL3 expression (!50%) by IHC, representing 67% of the overall population. The main grade 3 and 4 treatment-related AEs were thrombocytopenia (12%), serosal effusions (11%), and skin toxicities (8%), and the recommended dose was two cycles at 0.3 mg/kg every 6 weeks. The nonrandomized phase II TRINITY study of Rova-T in patients with heavily pretreated DLL3-positive SCLC is ongoing, as are phase III trials of Rova-T as second-line and maintenance therapy.
130 DLL3 is part of the Notch pathway, which is yet to be successfully targeted. A randomized phase II trial testing tarextumab, a Notch-inhibitor, in combination with platinum-etoposide chemotherapy in patients with extensive-stage SCLC, failed to show any significant improvement in PFS, ORR, or OS, and no predictive value was found for Notch pathway activation. 131 Other combinations have recently been tested in patients with SCLC. A randomized trial demonstrated that veliparib, a poly(ADP-ribose) polymerase 1 inhibitor, combined with platinum-based chemotherapy, slightly improved PFS over chemotherapy alone, without any significant difference in OS. 132 Trilaciclib, 133 a cyclin-dependent kinase 4 and cyclin-dependent kinase 6 inhibitor, combined with chemotherapy showed a confirmed 88% ORR in 19 patients with extensive-stage SCLC, but these results are too preliminary to draw definitive conclusions. A drug that deserves further exploration is lurbinectedin, a DNA-damaging agent that has been tested in a multicohort study as monotherapy or in combination with doxorubicin or paclitaxel. 134 Lurbinectedin gave an ORR of 36% to 67% and median PFS of 3 to 5 months; however, toxicity was quite high, with a febrile neutropenia rate of 11% to 36%. In patients with pretreated extended-stage SCLC, the association of lurbinectedin and doxorubicin is currently being compared with topotecan or a cyclophosphamide-doxorubicinvincristine combination in the phase III ATLANTIS trial. 135 
MPM
This year, interesting studies have been reported in patients with advanced malignant pleural mesothelioma (MPM), highlighting the promising role of ICIs in this population. In the IFCT-1501 MAPS2 phase II study, 125 patients with pretreated advanced mesothelioma (!2 lines or !1 with platinum-pemetrexed) were randomized to receive nivolumab versus nivolumab plus ipilimumab (1 mg/kg every 6 weeks) in two noncomparative arms. The primary end point was disease control rate (DCR) at 12 weeks. Both arms reached their primary end point, with DCRs of 44% and 50% for the nivolumab and combination arms, respectively; toxicity was higher in the combination arm, but globally manageable. With a median follow-up of 10.4 months, the median PFS was 4.0 months with nivolumab and 5.6 months with the combination, and the median OS times were 10.4 months and NR, respectively. 5 To date, the DETERMINE study is the only comparative study testing ICIs in MPM. This randomized, double-blind phase IIb trial compared tremelimumab, a CTLA4 inhibitor, with placebo as second-or third-line treatment in advanced MPM. Of 571 patients randomized, 569 received treatment (380 with 10 mg/kg of tremelimumab and 189 with placebo every 4 weeks times seven doses and then every 12 weeks). No significant differences in OS (primary end point) were observed (7-8 months for both treatment arms), and higher toxicity was reported with tremelimumab. 136 Finally, the KEYNOTE-028 phase Ib trial, assessed the safety and efficacy of pembrolizumab in 25 patients with previously treated MPM with PD-L1 expression of 1% or higher. The ORR was 20% (95% CI: 6.8-40.7) and the DCR was 72%. Responses were durable, with a median duration of 12 months (95% CI: 3.7-NR). 4 The role of antiangiogenic agents in MPM was confirmed by the LUME-Meso phase II trial which compared nintedanib plus platinum-pemetrexed to placebo plus platinum-pemetrexed in epithelioid or biphasic MPM. 137 The updated analysis showed meaningful improvements in PFS (9.4 versus 5.7 months [p ¼ 0.01], primarily in the epithelioid histologic type) and ORR (57% versus 44%), with a nonsignificant trend in OS benefit (18 versus 14 months [p ¼ 0.31]). Treatmentrelated grade 3 or 4 toxicities were increased ALT level (14%) and diarrhea (7%).
Finally, the expansion cohort of the phase I TRAP study testing ADI-PEG20, an arginine-degrading agent in combination with cisplatin-pemetrexed showed an encouraging ORR (35%), PFS (5.6 months), and OS (10.1 months) in MPM with loss of argininosuccinate synthase 1. 138 However, hematologic grade 3 or 4 treatment-related AEs occurred in around 30% of patients. On the basis of these results, the ATOMIC-meso randomized phase II/III study is currently testing the combination of ADI-PEG20 and cisplatin-pemetrexed versus first-line platinum-pemetrexed chemotherapy in patients with MPM with argininosuccinate synthase 1 loss. 139 
Thymic Malignancies
In the phase Ia JAVELIN study, eight patients with thymic epithelial tumors (thymoma and thymic carcinoma) received durvalumab, five at 10 mg/kg and three at 20 mg/kg. Three of the eight patients (38%) experienced a partial response. 2 A phase II study of pembrolizumab in patients with refractory thymic epithelial tumors was recently presented. Patients who progressed after platinum-containing chemotherapy received 200 mg of pembrolizumab every 3 weeks. A total of 33 patients were enrolled (26 with thymic carcinoma and seven with thymoma). The ORR and DCR were 24% and 76%, respectively. Observed grade 3 or 4 irAEs included hepatitis (12%), myocarditis (9%), myasthenia gravis (6%), and thyroiditis (3%). The rate of discontinuation due to irAEs was 24%. 3 A twin phase II study testing pembrolizumab in patients with thymic carcinoma showed an ORR of 22.5% and again a high incidence of irAEs (myocarditis, hepatitis, and thyroid disfunctions) probably because of a worsening of autoimmune disorders typically observed in patients with thymic malignancies. 140 
Conclusion
During the course of 2017, several studies reshaped the treatment paradigm of advanced NSCLC. ICIs have a confirmed long-term survival benefit in pretreated patients and in untreated patients with PD-L1 expression of 50% or higher. In the first-line setting, anti-PD-1/PD-L1 agents in combination with chemotherapy or anti-CTLA4 showed promising preliminary results. In patients with EGFR or ALK-positive NSCLC, efficacy of ICIs was limited; however, predictive biomarkers (notably PD-L1) could be useful to identify potential responders. In addition, preliminary data suggest a benefit from continuing immune checkpoint blockade until disease progression, and correlations between drug exposure or AEs and activity of ICIs were recently reported. PD-L1 was not a reliable biomarker for atezolizumab efficacy in second or further lines, and different competitive predictive biomarkers such as TMB came of age. Finally, acceleration of tumor growth during ICI treatment was described for the first time in a subgroup of patients with NSCLC and appeared to correlate with poor survival.
Regarding oncogene-addicted NSCLC, nextgeneration TKIs for EGFR (osimertinib) and ALK (alectinib) showed promising activity and PFS compared with first-generation drugs; however, given the lack of mature OS data the best treatment strategy is yet to be determined. New potent drugs (lorlatinib, entrectinib, and larotrectinib) showed encouraging results in ROS1-or NTRK-rearranged NSCLC. Finally, RET-rearrangements and BRAF, MET exon 14, and HER2 mutations joined the list of targetable oncogenic drivers, with favorable responses for different TKIs as monotherapy or in combination (dabrafenib plus trametinib in patients with BRAF-mutated NSCLC).
On the other hand, treatment of SCLC, MPM, and thymic malignancies did not experience any major changes in 2017. For SCLC, preliminary data suggest a potential benefit with ICIs, and remarkable clinical activity was seen with anti-DDL3 therapies (Rova-T) and novel chemotherapeutic agents (lurbinectedin). Finally, ICIs showed compelling results in MPM or thymic malignancies, and it is hoped that future studies will provide physicians and patients with promising new therapeutic options.
